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THE aim of this study was to evaluate plasma
levels of two mediators with immunosuppressive
properties, complement fraction C3a (C3a) and
transforming growth factor-l (TGF-I), during
extracorporeal circulation. The proliferation
index after phytohaemagglutinin (PHA) stimula-
tion of isolated peripheral blood mononuclear
cells was also investigated. Sixteen patients
undergoing hypothermic (n 8, group 1) and nor-
mothermic (n=8, group 2) cardiopulmormry
bypass (CPB) were enrolled in this study. As a
control, we evaluated four patients undergoing
thoracovascular operations without CPB. Blood
samples were collected before CPB but after
anaesthesia, every 30 rain during CPB, at the end
of CPB and 10 rain after protamine administra-
tion. Both C3a and TGF-I increased significantly
during CPB and after protamine administration
in the hypothermic as well as the normothermic
group. In the latter case the increase of C3a and
TGF-I, although more prominent, was not sig-
nificantl higher than in the former group. Con-
versely, the proliferation, index of peripheral
mononuclear cells had already decreased 30 rain
after CPB was started and remained depressed
throughout the CPB time. These results suggest a
possible role of C3a and TGF-I in the immuno-
logical changes occurring during extracorporeal
circulation.
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Introduction
Current knowledge on cardiopulmonary
bypass (CPB) suggests that complement activa-
tion and release of inflammatory mediators from
activated platelets and polymorphonucleates into
the bloodstream, is one of the most important
pathophysiological changes occurring during
extracorporeal circulation, and probably is
responsible for a number of postoperative
derangements such as the increase of capillary
permeability, systemic vasodilatation and multiple
organ dysfunction.>
Recently, it has been reported that the media-
tors released during CPB may also play a deter-
minant role in the biochemical and clinical
events, leading to the postoperative immunosup-
pression in cardiac surgery patients throughout a
functional and quantitative decrease of T- and B-
lymphocytes.
4 Experimental investigations
showed that T-helper number, mitogen respon-
siveness and interleukin-2 production significantly
decreased on the first postoperative day and
remained depressed even on day 7.5 Although
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high levels of cortisol may be a cause of the
impairment of the immune system with a redis-
tribution of circulating lymphocytes to lymphoid
organs and bone marrow,
6 other inhibitory
factors may be released during the CPB techni-
que.
As suggested by our previous study,
7 using iso-
lated T-lymphocytes, an inhibition of proliferation
and cytokine production appears 30 min after
the onset of CPB. To evaluate the causes of this
early immunological defect during CPB, we have
focused our attention on the plasma levels of
two mediators with immunosuppressive effects,
complement fraction C3a (C3a), and transform-
ing growth factor-[31 (TGF-31).
It is known that C3a, a soluble fragment
derived from complement, suppresses antigen-
induced T-cell proliferation, antibody production,
T-cell and natural killer (NK) cell mediated cyto-
toxicity, as reported by studies in vitro and in
vivo.
8 TGF-I, a cytokine mainly released from
the alpha granules of the activated platelets, is a
multifunctional mediator that affects cell growth
and differentiation, immunoresponses, angio-
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genesis and tissue repair.9’ The findings that
receptors for TGF-[31 are ubiquitous further
suggests that this substance may have an impor-
tant role as a regulatory molecule. No data have
been reported so far on its presence during
CPB.
The aim of this study was to determine
whether CPB was associated with a change of
C3a and TGF-[31 plasma concentration and
possibly with the decrease of in vitro T-cell pro-
liferation. In recent years, a number of investiga-
tors have suggested the superiority of
normothermic heart surgery compared to hypo-
thermic heart surgery to reduce the adverse con-
sequences of intraoperative myocardial ischaemia
and cardiopulmonary bypass. Both approaches
have shown advantages and disadvantages, and
data are not conclusive. To evaluate the pos-
sible differences in the activation of the inflam-
matory system, we have performed our study in
normothermic (35-37C) and hypothermic
(30C) CPB.
Materials and Methods
Sixteen patients undergoing extracorporeal cir-
culation for coronary artery bypass disease were
enrolled in this study. The patients were ran-
domized in two groups: group 1 (eight patients)
received hypothermic CPB and group 2 (eight
patients) received normothermic CPB. There was
no significant difference between the two groups
with respect to the age of the patients and CPB
times. The patients’ characteristics are reported
in Table 1. As a control, blood samples were
drawn at the indicated times after anaesthesia in
four patients undergoing thoracovascular opera-
tion without CPB. The influence of anaesthesia
was eliminated by taking the baseline value after
its induction, just before CPB or thoracovascular
operation. It must be mentioned that, for ethical
reasons, we could not check the influence of
protamine in these controls.
Anaesthesia was uniform in all cases and con-
sidered of a standard combination of fentanyl
citrate, diazepam, pancuronium bromide and iso-
flurane CPB equipment consisted of a non-
pulsatile roller pump, a membrane oxygenator
and an arterial filter. Myocardial protection was
Table 1. Patients" characteristics
Characteristic Hypothermic Normothermic
Age (Y) 62 -t- 4 64 __+ 4
Sex (M:F) 6:2 5:3
Grafts (NR) 3 -t- 3 -t-
CPB time 110 -I- 10 100 -t- 6
performed in group 1 with anterograde cold
blood cardioplegic solution as described by
Buckberg,
2 and in group 2 with continuous
intermittent normothermic blood cardioplegia as
reported by Lichtenstein.3 In patients under-
going cold CPB, the temperature of the circulat-
ing blood was cooled to 30C, whereas those in
the warm group were kept between 35 and
37C. Pump flows were maintained at 2.51/min/
m
2 in normothermic CPB, and about 2.21/min/
m
2 in hypothermic CPB. Administration of
heparin before cannulation and subsequent neu-
tralization after bypass with protamine sulfate
were performed in a standard fashion.
Whole-blood samples (5 ml) for C3a and TGF-
fl determination were drawn before CPB (T1)
but after anaesthesia at 30 (T2), 60 (T3) and 90
(T4) min during CPB, immediately before the
end of CPB (T5), and 10 min after protamine
administration (T6). After platelets count, blood-
EDTA was immediately centrifuged and the
plasma was stored at -80C until assayed.
C3a was measured in the plasma samples by
radioimmunoassay
4 and corrected for haemodi-
lution (haematocrit of sample/haematocrit before
CPB x 100). Data were expressed as ng/ml.
TGF-]31 (expressed as ng/ml of plasma) was
measured by ELISA by using the method and the
reagents kindly provided by Dr W. Waegell of
Celtrix Laboratories Inc., Palo Alto, CA, US.& In
this preliminary investigation we have not
.attempted to measure the TGF-]3 in a latent
form9’15 so that reported values are only for the
biologically mature form. All plasma samples
were diluted at least 1:1 with the appropriate
diluent. A three-cycle automatic washing was rou-
finely performed. Negative plasma samples, in the
absence or presence of haemoglobin, were
spiked with the cytokine standards to assess the
reliability and precision of the various assays.
Yields ranged between 86 and 107%.
For in vitro T-cell isolation, samples of venous
blood (10ml) were obtained from each patient
of both groups at the following times: before the
institution of CPB, at 30 and 60 min during CPB
and at the end of CPB.
After a gradient of Lymphoprep and centrifuga-
tion, peripheral blood mononuclear cells
(PBMC) were removed, resuspended in medium
and incubated, following the standard procedure.
The proliferative response of PBMC to phytohae-
magglutinin (PHA) was determined using the col-
orimetric method described by Mosmann,
6
based on the tetrazolium salt 3-(4,5 dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
Briefly, 2 x 105 cells/well were incubated in
2001 of culture medium in the presence or
absence of PHA for 40 h. After removing 1001
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of medium, 10 gl of a solution of MTT (5 mg/ml)
was added to each well and incubated at 37C.
After 4 h 100 Ill of acid propan-2-ol (0.04M HCl
in propan-2-ol) was added to each well and after
all the formazan crystals had dissolved, the plate
was read on a microelisa reader. The optical
density values (O.D.) were obtained, using a text
wavelength of 570nm and a reference wave-
length of 630nm. The proliferation index (PI),
used to quantitate the PBMC response to PHA,
was calculated as PI PHA treated lymphocyte
activity (O.D.)/untreated lymphocyte activity
(O.D.).
Statistical analysis: Data were expressed as the
mean _+ S.E.M. For intragroup analysis, a Stu-
dent’s t-test for paired data was used. Intergroup
differences were estimated by the ANOVA test.
p < 0.05 was assumed to be significant.
Results
Thirty min after the start of CPB (T2), the
plasma level of C3a increased from its baseline
value in both groups (2621 _+ 355ng/ml vs.
287 +__ 37 ng/ml, group 1, hypothermia;
2632 +_ 626 ng/ml vs. 262 + 18ng/ml, group 2,
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FIG. 1. Time course of C3a plasma levels during hypothermic
(white bars) and normothermic (black bars) cardiopulmonary
bypass. T1 before CPB and after anaesthesia; T2 30 min
after CPB was started; T3 60 min after CPB was started; T4
90 min after CPB was started; T5 immediately before CPB
end; T6 10 min after protamine administration. *p < 0,05 vs.
T1, group 1" +p < 0.05 vs. T1, group 2. I-], hypothermic CPB; ,,
normothermic CPB.
normothermia; p < 0.01), and it remained high
during the CPB period (Fig. 1). In the controls
without CPB the plasma level of C3a increased
towards the end of the operation but it tended
to normalize quickly (Table 2). After protamine
administration, C3a rose in both normothermic
and hypothermic CPB (2875_ 506 ng/ml, group
1; 3275-t-684ng/ml, group 2). Although nor-
mothermic C3a values were higher than hypo-
thermic ones, no significant intergroup
differences were evident.
TGF-J31 increased significantly after 30 min of
extracorporeal circulation (6.24 -t- 1.75 vs.
1.6 -t- 0.23, group 1; 9.73 2.14ng/ml vs.
2.35 + 0.36 ng/ml, group 2, p < 0.05). Also in this
case, high levels of TGF-131 persisted until CPB
ended in both groups. No change of TGF-131
plasma levels was noted in the control group
(Table 2). Unexpectedly, peak values of
TGF-131 were reached 10 min after protamine
administration (25.93 _+ 6.39 ng/ml, group 1;
39.2 +_ 5.44ng/ml, group 2). TGF-]31 in nor-
mothermic extracorporeal circulation was con-
sistently higher than in hypothermic CPB
(Fig. 2). However the difference was not statisti-
cally significant.
Platelet numbers (x 1,000) showed a fall 30
min after the onset of CPB in both groups
(161 +__ 18 vs. 276 29, group 1; 167 35 vs.
242 32, group 2) not obseed in the controls.
There was a slight increase during CPB, followed
by a decreased level after protamine administra-
tion (Fig. 3). Without CPB (control group) plate-
let levels did not vary (Table 2).
To evaluate the effect of CPB on cell pro-
liferation, PBMC were isolated from blood
samples during CPB and a similar number of
cells were cultured in the presence or absence of
PHA (5 Ig/ml). At variance with the controls, the
proliferation index (PI) was greatly affected
during CPB, as shown in Fig. 4. PI significantly
decreased as soon as 30 min after CPB com-
menced (PI at 30 min, 1.26 4- 0.08 vs.
1.59 _+ 0.09 of baseline value, group 1; PI at 30
rain, 1.36 4- 0.04 vs. 1.74 4- 0.06 of baseline value,
group 2; p< 0.01); at the end of CPB the PI
decreased further (1.23 4- 0.05 group 1,
p < 0.05; 1.58 4- 0.06 group 2, p < 0.05). There
was also a slight, but not significant decrease of
Table 2. Values with mean -i- S.E.M. of C3A, TGF-II, platelets and proliferation index obtained from four control
samples undergoing a thoracovascular operation
Time C3a (ng/ml) TGF-I (ng/ml) PLT (x 1,000) PI(M]-I’)
T1 (after anaesthesia)
T5 (before the end of the operation)
T6 (30 min after operation)
200 -I- 30 1.37 -!- 0.27 270 -I- 33 1.48 -!- 0.22
610 -I- 100 1.47 _____
0.15 256 -I- 28 1.34 -I- 0.19
345 -I- 86 1.35 ___+ 0.18 262 -I- 42 1.36 __-+ 0.25
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FIG. 2. Time course of TGF-I]I plasma levels during hypothermic
(white bars) and normothermic (black bars) CPB. T1 before
CPB; T2 30 min after CPB was started; T3 60 min after CPB
was started; T4 90 min after CPB was started; T5 immedi-
ately before CPB end; T6 10 min after protamine administra-
tion. *p< 0.05 vs. T1, group 1; +p < 0.05 vs. T1, group 2. Key
as in Fig. 1.
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FIG. 3. Platelet (PLT) count during hypothermic (white bars) and
normothermic (black bars) CPB. T1 before CPB; T2 30 min
after CPB was started; T3 60 min after CPB was started; T4
90 min after CPB was started; T5 immediately before CPB
end; T6 10 min after protamine administration. *p < 0.05 vs.
T1, group 1; +p < 0.05 vs. T1, group 2. Key as in Fig. 1.
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FIG. 4. Proliferation index of circulating lymphocytes after isola-
tion and PHA stimulation during hypothermic (white bars) and
normothermic (black bars) CPB. T1 before CPB; T2 30 min
after CPB was started; T3 60 min after CPB was started; T4
immediately before CPB end. *p<0.05 vs. T1, group 1"
+p < 0.05 vs. T1, group 2. Key as in Fig. 1.
the PI during the thoracovascular operation
(Table 2).
Discussion
CPB causes a number of inflammatory and
immunologic responses, documented in a series
of studies,a- by the increased plasma levels of
several compounds which are not readily corre-
lated with the physiopathological modifications.
Clinical observation on the increased suscept-
ibility to infections in postoperative cardiac
patients has suggested a CPB related T- and B-
cell immunodeficiency.
7 Profound lymphopenia
with drastic reduction in T-helper-lymphocytes
was reported from 24 h to 3-4 days after opera-
tion,
17 and other investigators found changes in
the CD4/CD8 ratio as early as 2 h after CPB. Our
recent study,
7 performed during CPB, showed
that lymphocyte function was already suppressed
30 min after CPB had commenced, and remained
throughout the CPB time. This interesting experi-
mental finding suggests that the cause of the
immunosuppression could be due to very early
events mainly occurring during extracorporeal
circulation.
It is well known that the complement system is
rapidly activated through the contact of blood
with foreign materials of the o_xygenator, and
8 18,19 recently it has been reported’ that comple-
ment by-products play an important modulatory
.role in the inductive phase of the immune
response, throughout a cooperation between
immobilized C3 split products (that stimulate T-
and B-cell activation) and the soluble C3a
product, which inhibit lymphocyte proliferation.
Moreover, other studies have shown that soluble
complement fragments generated during decom-
plementation may be immunosuppressive,s Thus,
the high levels of C3a during CPB determined in
the present study (Fig. 1) agree with the possibi-
lity of an immunosuppressive effect.
Perhaps the best known effect of TGF-131 is on
the cells of the immune system: TGF-[I inhibits
T- and B-cell proliferation without affecting IL-2
or IL-2 receptor expression, and also inhibits NK
20 21 cell activity. Data reported in our study indi-
cate that during extracorporeal circulation, the
decrease of platelets and their degranulation is
concomitant with the release of TGF-]]I from the
alpha granules, with its consequent increase in
the bloodstream. Because TGF-I mediates the
immunodepressive effects at levels in the fento-
molar ranges, it appears reasonable to postulate
that binding of TGF-fll to circulating immune
cells may lead later to their hyporesponsiveness
to PHA, as shown by the. decrease of the PI in
Fig. 4. Furthermore, it is well known that prot-
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amine administration causes an activation of the
classic pathway of the complement system. The
concomitant increase of circulating levels of C3a
and TGF-[31 and the fall of platelet count, 10 min
after protamine administration, are presumably
linked to complement changes and platelet
degranulation.
As far as the comparison between normother-
mic and hypothermic CPB is concerned, it has
been reported previously that hypothermia
causes an inhibition of complement activation
and platelet degranulation. Experimental
studies> have further shown that hypothermia
decreases the capacity of serum to generate C3a
and C4a in response to a known complement
activator (zymosan), with a reversible defect in
platelet function. Our investigation is in agree-
ment with this results, because we have found a
consistent reduction, although not significant, in
plasma levels of C3a and TGF-J31 during hypo-
thermic CPB in comparison to the normothermic
technique. This thermic effect is particularly
evident in platelet activation and degranulation
which slightly affected the C3a production.
Further studies are needed to clarify the optimal
temperature for the preservation of the circula-
tion homeostasis.
In conclusion, our study suggests that the
increased levels of plasma C3a and TGF-J31 seem
temporarily related to the inhibition of T-cell
proliferation observed during CPB. Because the
immunosuppressive effects of these molecules
are reported for in vitro and in vivo studies, we
can speculate that these mediators as well as
others not evaluated here, are responsible for the
immunodepression observed in cardiac patients
undergoing CPB.
A final comment concerns the pleiotropic
activity of TGF-122 so that it can exert either
protective or damaging effects during CPB. As an
example, TGF-[31 may be associated with the
thermotolerance. Thermotolerance can generally
be defined as the ability of an organism to with-
stand an otherwise lethal stress due to pretreat-
ment with a nonlethal stress. The stress could
result from a number of insults such as hyper-
thermia and oxidative injury which can induce
expression of heat stress proteins (HSP) as an
acute response. Furthermore, the well recognized
role of TGF-[31 as a mediator in tissue repair
suggests that its increased generation after the
perturbation of cellular homeostasis could be
beneficial in promoting recovery of cells and
healing.
22 Thus we are now planning to evaluate
an immunoadjuvating treatment carried out
before and after CPB to prevent or reduce the
immunosuppression that may favour septic com-
plications after surgery.
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